Skip to main content

Advertisement

Log in

SGLT2 inhibitors and cardiovascular and renal outcomes: a meta-analysis and trial sequential analysis

Heart Failure Reviews Aims and scope Submit manuscript

Abstract

Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce cardiovascular events and renal outcomes in patients with diabetes mellitus (DM). This meta-analysis aimed to provide a thorough evaluation regarding the efficacy and safety of SGLT2 inhibitors. Data search of MEDLINE/PubMed, Embase, and Cochrane Library databases and ClinicalTrials.com from inception through November 26, 2020. We included randomized trials, SGLT2 inhibitors compared with placebo, patients with or without diabetes at recruitment, and reporting the incidence of cardiovascular or renal outcomes. Two authors extracted pertinent data into predefined data collection tables. Ten trials were included (71,553 patients). The mean age was 64.7 ± 8.4 years, with 65.1% male. Follow-up durations range 9–50 months. Inhibition of SGLT2 resulted in lower composite outcome of heart failure (HF) hospitalization or cardiovascular death (RR 0.76, 95% CI 0.73–0.81, P < 0.01) and lower risk of renal outcomes (RR 0.68, 95% CI 0.60–0.77, P < 0.01). Furthermore, SGLT2 inhibitors were associated with lower major adverse cardiovascular events (MACEs), HF hospitalization, cardiovascular mortality, all-cause mortality, myocardial infarction, and serious adverse events, compared with placebo (P < 0.05). Sensitivity analyses revealed lower MACE events also in patients with HF, and a lower HF hospitalization and cardiovascular mortality in non-diabetic patients (P < 0.05). While the amputation risk was comparable between the two groups, the risk of diabetic ketoacidosis was higher in the SGLT2 inhibitor group. Inhibition of SGLT2 in patients with DM and prevalent ASCVD reduces the risk of HF hospitalization, cardiovascular mortality, all-cause mortality, MACE, and renal outcomes without increasing the risk of serious adverse events or amputation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Whiting DR, Guariguata L, Weil C, Shaw J (2011) IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 94:311–321. https://doi.org/10.1016/j.diabres.2011.10.029

    Article  PubMed  Google Scholar 

  2. Roger VL, Go AS, Lloyd-Jones DM et al (2011) Heart disease and stroke statistics–2011 update: a report from the American Heart Association. Circulation 123:e18–e209. https://doi.org/10.1161/CIR.0b013e3182009701

    Article  PubMed  Google Scholar 

  3. Ahmad FS, Ning H, Rich JD et al (2016) Hypertension, obesity, diabetes, and heart failure-free survival: the cardiovascular disease lifetime risk pooling project. JACC Heart failure 4:911–919. https://doi.org/10.1016/j.jchf.2016.08.001

    Article  PubMed  PubMed Central  Google Scholar 

  4. Yancy CW, Jessup M, Bozkurt B et al (2017) 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Cardiac Fail 23:628–651. https://doi.org/10.1016/j.cardfail.2017.04.014

    Article  Google Scholar 

  5. Ogurtsova K, da Rocha Fernandes JD, Huang Y et al (2017) IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract 128:40–50. https://doi.org/10.1016/j.diabres.2017.03.024

    Article  CAS  PubMed  Google Scholar 

  6. American Diabetic Association (2020) 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2020. Diabetes Care 43:S98–S110. https://doi.org/10.2337/dc20-S009

  7. Gallo LA, Wright EM, Vallon V (2015) Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences. Diab Vasc Dis Res 12:78–89. https://doi.org/10.1177/1479164114561992

    Article  CAS  PubMed  Google Scholar 

  8. McMurray JJV, Solomon SD, Inzucchi SE et al (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381:1995–2008. https://doi.org/10.1056/NEJMoa1911303

    Article  CAS  PubMed  Google Scholar 

  9. Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117–2128. https://doi.org/10.1056/NEJMoa1504720

    Article  CAS  PubMed  Google Scholar 

  10. Perkovic V, Jardine MJ, Neal B et al (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380:2295–2306. https://doi.org/10.1056/NEJMoa1811744

    Article  CAS  PubMed  Google Scholar 

  11. Packer M (2020) SGLT2 inhibitors produce cardiorenal benefits by promoting adaptive cellular reprogramming to induce a state of fasting mimicry: a paradigm shift in understanding their mechanism of action. Diabetes Care 43:508–511. https://doi.org/10.2337/dci19-0074

    Article  CAS  PubMed  Google Scholar 

  12. Wiviott SD, Raz I, Bonaca MP et al (2019) dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380:347–357. https://doi.org/10.1056/NEJMoa1812389

    Article  CAS  PubMed  Google Scholar 

  13. Cannon CP, Pratley R, Dagogo-Jack S et al (2020) Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med 383:1425–1435. https://doi.org/10.1056/NEJMoa2004967

    Article  CAS  PubMed  Google Scholar 

  14. Bhatt DL, Szarek M, Pitt B et al (2020) Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med. https://doi.org/10.1056/NEJMoa2030186

    Article  PubMed  Google Scholar 

  15. Bhatt DL, Szarek M, Steg PG et al (2020) Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. https://doi.org/10.1056/NEJMoa2030183

    Article  PubMed  Google Scholar 

  16. Neal B, Perkovic V, Mahaffey KW et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377:644–657. https://doi.org/10.1056/NEJMoa1611925

    Article  CAS  PubMed  Google Scholar 

  17. Liberati A, Altman DG, Tetzlaff J et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 62:e1-34. https://doi.org/10.1016/j.jclinepi.2009.06.006

    Article  PubMed  Google Scholar 

  18. Thorlund K, Devereaux PJ, Wetterslev J et al (2009) Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses? Int J Epidemiol 38:276–286. https://doi.org/10.1093/ije/dyn179

    Article  PubMed  Google Scholar 

  19. Heerspink HJL, Stefánsson BV, Correa-Rotter R et al (2020) Dapagliflozin in patients with chronic kidney disease. N Engl J Med. https://doi.org/10.1056/NEJMoa2024816

    Article  PubMed  Google Scholar 

  20. Packer M, Anker SD, Butler J et al (2020) Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. https://doi.org/10.1056/NEJMoa2022190

    Article  PubMed  Google Scholar 

  21. Arnett DK, Blumenthal RS, Albert MA et al (2019) 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 140:e563–e595. https://doi.org/10.1161/CIR.0000000000000677

    Article  PubMed  PubMed Central  Google Scholar 

  22. Das SR, Everett BM, Birtcher KK et al (2018) 2018 acc expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a report of the American College of Cardiology Task Force on Expert Consensus Dec. J Am Coll Cardiol 72:3200–3223. https://doi.org/10.1016/j.jacc.2018.09.020

    Article  PubMed  Google Scholar 

  23. American Diabetic Association (2018) 9. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2018. Diabetes Care 41:S86–S104. https://doi.org/10.2337/dc18-S009

  24. Packer M, Anker SD, Butler J et al (2017) Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure: proposal of a novel mechanism of action. JAMA Cardiol 2:1025–1029. https://doi.org/10.1001/jamacardio.2017.2275

    Article  PubMed  Google Scholar 

  25. Verma S, McMurray JJV (2018) SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia 61:2108–2117. https://doi.org/10.1007/s00125-018-4670-7

    Article  CAS  PubMed  Google Scholar 

  26. Bonnet F, Scheen AJ (2018) Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: The potential contribution to diabetes complications and cardiovascular disease. Diabetes Metab 44:457–464. https://doi.org/10.1016/j.diabet.2018.09.005

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Contributions

All the included authors contributed significantly to accomplish this study. Dr. Barbarawi had full access to all data in the study and take responsibility for the integrity and accuracy of the data analysis. Concept and design: Barbarawi, Chen. Acquisition, analysis, or interpretation of data: Barbarawi, O. Barbarawi, Alabdouh, Lakshman, Chen. Drafting of the manuscript: Barbarawi, Chen. Critical revision of the manuscript for important intellectual content: Barbarawi, O. Barbarawi, Alabdouh, Lakshman, Chen. Statistical analysis: Barbarawi, Alabdouh, O. Barbarawi. Administrative, technical, or material support: Barbarawi, Alabdouh, O. Barbarawi. Supervision: Barbarawi, Chen.

Corresponding author

Correspondence to Mahmoud Barbarawi.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 2535 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Barbarawi, M., Al-abdouh, A., Barbarawi, O. et al. SGLT2 inhibitors and cardiovascular and renal outcomes: a meta-analysis and trial sequential analysis. Heart Fail Rev 27, 951–960 (2022). https://doi.org/10.1007/s10741-021-10083-z

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10741-021-10083-z

Keywords

Navigation